|
$m
|
% change
|
|
Actual1
|
CER2
|
||
Total
Revenue
|
5,405
|
(12)
|
(10)
|
Product Sales
|
4,843
|
(13)
|
(12)
|
Externalisation Revenue
|
562
|
2
|
3
|
|
|
|
|
Reported
Operating Profit
|
917
|
(12)
|
(23)
|
Core3
Operating Profit
|
1,667
|
5
|
(2)
|
|
|
|
|
Reported
Earnings Per Share (EPS)
|
$0.42
|
(17)
|
(35)
|
Core
EPS
|
$0.99
|
4
|
(4)
|
Regulatory Approvals
|
Tagrisso - lung cancer (US, EU;
full approval)
|
Tagrisso - lung cancer
(CN)
|
|
Forxiga - type-2 diabetes
(CN)
|
|
Qtern - type-2 diabetes
(US)
|
|
Siliq - psoriasis (US; by
partner)
|
|
Regulatory Submission Acceptances
|
Lynparza - ovarian cancer (2nd
line) (US) (Priority Review)
|
Bydureon - type-2 diabetes
(autoinjector) (US)
|
|
Symbicort - COPD exacerbations
(US)
|
|
benralizumab - severe, uncontrolled asthma (JP)
|
|
Phase III or Major Data Readouts
|
Lynparza - breast
cancer
|
Farxiga - type-2 diabetes
(CVD-REAL real-world study)
|
|
Other Key Developments
|
Orphan Drug Designation: Lynparza - ovarian cancer (JP)
|
Complete Response Letter: ZS-9 (sodium zirconium cyclosilicate) -
hyperkalaemia (US)
|
|
Orphan designation: inebilizumab - neuromyelitis optica spectrum
disorder (EU)
|
Total Revenue
|
A low
to mid single-digit percentage decline
|
Core EPS
|
A low
to mid teens percentage decline*
|
Q2
2017
|
Faslodex - breast cancer (1st line): Regulatory decision
(JP)
Lynparza - ovarian cancer (2nd line): Regulatory submission
(EU)durvalumab (durva) - bladder cancer: Regulatory decision
(US)
acalabrutinib - blood cancer: Data readout, regulatory submission
(US) (Phase II)#
Bevespi - COPD: Regulatory submission (EU)
|
Mid-2017
|
durva
+/- tremelimumab (treme) - lung cancer (MYSTIC): Data
readout
|
H2
2017
|
Faslodex - breast cancer (1st line): Regulatory decision
(US, EU)
Lynparza - ovarian cancer (2nd line): Regulatory decision
(US)
Lynparza - breast cancer: Regulatory submission
Lynparza - ovarian cancer (1st
line): Data readout
Tagrisso - lung
cancer (1st line): Data readout
durvalumab
- lung cancer (PACIFIC): Data readout, regulatory submission
(US)durva +/- treme - lung cancer (ARCTIC): Data readout,
regulatory submission
durva +/- treme - lung cancer (MYSTIC): Regulatory
submission
durva +/- treme - head & neck cancer (KESTREL): Data readout
moxetumomab - leukaemia: Data readout
Bydureon - cardiovascular (CV) outcomes trial: Data readout, regulatory
submission
benralizumab - severe, uncontrolled asthma: Regulatory decision
(US)
tralokinumab - severe, uncontrolled asthma: Data
readout
|
2018
|
Lynparza - ovarian cancer (1st line): Regulatory
submission
Tagrisso - lung cancer (1st line): Regulatory
submission
durva +
treme - lung cancer (NEPTUNE): Data readout
durva +/- treme - head & neck cancer (KESTREL): Regulatory
submission
durva
+/- treme head & neck cancer (EAGLE): Data readout,
regulatory submission
durva
+/- treme - bladder cancer (DANUBE): Data readout, regulatory
submission
moxetumomab
- leukaemia: Regulatory submission
selumetinib
- thyroid cancer: Data readout, regulatory submission
Bydureon - autoinjector: Regulatory decision
(US)
roxadustat
- anaemia: Data readout
(AstraZeneca-sponsored trials), regulatory
submission
Duaklir - COPD: Regulatory submission (US)benralizumab -
severe, uncontrolled asthma: Regulatory decision (EU,
JP)
benralizumab - COPD: Data readout, regulatory
submission
tralokinumab
- severe, uncontrolled asthma: Regulatory submission
PT010 -
COPD: Data readout, regulatory submission
anifrolumab
- lupus: Data
readout
|
Media
Enquiries
|
||
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
Investor
Relations
|
||
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases (CVMD)
|
+1 240
543 7970
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
|
$m
|
% change
|
|
Actual
|
CER
|
||
Product
Sales
|
4,843
|
(13)
|
(12)
|
Externalisation
Revenue
|
562
|
2
|
3
|
|
|
|
|
Total Revenue
|
5,405
|
(12)
|
(10)
|
Growth Platform
|
$m
|
% change
|
|
Actual
|
CER
|
||
Emerging
Markets
|
1,562
|
7
|
9
|
Respiratory
|
1,181
|
(2)
|
-
|
New
CVMD
|
798
|
5
|
6
|
Japan
|
450
|
5
|
3
|
New
Oncology
|
236
|
n/m
|
n/m
|
|
|
|
|
Total*
|
3,572
|
4
|
5
|
|
$m
|
% of Total
|
% change
|
|
Actual
|
CER
|
|||
Royalties
|
45
|
8
|
18
|
24
|
Milestones
|
136
|
24
|
44
|
50
|
|
|
|
|
|
Total Sustainable and Ongoing Externalisation Revenue
|
181
|
32
|
37
|
42
|
|
|
|
|
|
Upfront Receipts
|
381
|
68
|
(9)
|
(9)
|
|
|
|
|
|
Total Externalisation Revenue
|
562
|
100
|
2
|
3
|
Medicine
|
Partner
|
Region
|
$m
|
Zoladex
|
TerSera
Therapeutics LLC (TerSera) - initial revenue
|
US and
Canada
|
250
|
Siliq (brodalumab)
|
Valeant
Pharmaceuticals International, Inc. (Valeant) - milestone
revenue
|
US
|
130
|
MEDI8897
|
Sanofi
Pasteur Inc. (Sanofi Pasteur) - initial revenue
|
Global
|
127
|
Other
|
|
|
55
|
Total
|
|
|
562
|
Announcement Date
|
Medicine
|
Partner
|
Region
|
Externalisation Revenue
|
3 March
2017
|
MEDI8897
|
Sanofi
Pasteur
|
Global
|
● Initial €120m
milestone
● Up to €495m
in sales and development-related milestones
|
20 February
2017
|
Zoladex
|
TerSera
|
US and
Canada
|
● Initial $250m
milestone
● Up to $70m in
sales-related milestones
● Mid-teen percentage
royalties on sales
|
4 October
2016
|
Toprol-XL
|
Aralez
Pharmaceuticals Inc.
|
US
|
● Initial $175m
milestone
● Up to $48m
milestone and sales-related revenue
● Mid-teen percentage
royalties on sales
|
1 July
2016
|
Tralokinumab - atopic dermatitis
|
LEO
Pharma A/S (LEO Pharma)
|
Global
|
● Initial $115m
milestone
● Up to $1bn in
commercially-related milestones
● Up to mid-teen
tiered percentage royalties on sales
|
9 June
2016
|
Anaesthetics
|
Aspen
Global Inc.
|
Global
(excl. US)
|
● Initial $520m
milestone
● Up to $250m in
sales-related revenue
● Double-digit
percentage trademark royalties on sales
|
1 September
2015
|
Siliq (brodalumab) -
psoriasis
|
Valeant
|
Global,
later
amended
to US
|
● Initial $100m
milestone
● Pre-launch
milestone of $130m
● Sales-related
royalties up to $175m
● Profit
sharing
|
19 March
2015
|
Movantik
|
Daiichi
Sankyo Company, Ltd (Daiichi
Sankyo)
|
US
|
● Initial $200m
milestone
● Up to $625m in
sales-related revenue
|
Medicine
|
Region
|
Agreement Completion Date
|
Q1 2016Impacted RegionProduct Sales ($m)
|
Anaesthetics
|
Global
(excl. US)
|
1 September 2016
|
134
|
Toprol-XL
|
US
|
31 October 2016
|
21
|
Bydureon
and Byetta
|
China
|
11 October 2016
|
3
|
|
|
|
|
Total
|
|
|
158
|
|
|
|
% change
|
|
|
$m
|
% of total*
|
Actual
|
CER
|
Oncology
|
|
|
|
|
Tagrisso
|
171
|
4
|
n/m
|
n/m
|
Iressa
|
124
|
3
|
(8)
|
(7)
|
Lynparza
|
57
|
1
|
30
|
32
|
|
|
|
|
|
Legacy:
|
|
|
|
|
Faslodex
|
214
|
4
|
13
|
13
|
Zoladex
|
185
|
4
|
4
|
5
|
Casodex
|
56
|
1
|
(10)
|
(8)
|
Arimidex
|
52
|
1
|
(9)
|
(7)
|
Others
|
26
|
1
|
24
|
24
|
Total Oncology
|
885
|
18
|
20
|
21
|
CVMD
|
|
|
|
|
Brilinta
|
224
|
5
|
24
|
27
|
Farxiga
|
207
|
4
|
25
|
25
|
Onglyza
|
154
|
3
|
(27)
|
(27)
|
Bydureon
|
153
|
3
|
13
|
14
|
Byetta
|
46
|
1
|
(26)
|
(24)
|
|
|
|
|
|
Legacy:
|
|
|
|
|
Crestor
|
631
|
13
|
(45)
|
(44)
|
Seloken/Toprol-XL
|
186
|
4
|
1
|
3
|
Atacand
|
75
|
2
|
4
|
7
|
Others
|
103
|
2
|
(18)
|
(16)
|
Total CVMD
|
1,779
|
37
|
(22)
|
(21)
|
Respiratory
|
|
|
|
|
Symbicort
|
677
|
14
|
(10)
|
(8)
|
Pulmicort
|
337
|
7
|
9
|
14
|
Daliresp/Daxas
|
44
|
1
|
42
|
42
|
Tudorza/Eklira
|
37
|
1
|
(5)
|
(3)
|
Duaklir
|
19
|
0
|
46
|
54
|
Others
|
67
|
1
|
3
|
6
|
Total Respiratory
|
1,181
|
24
|
(2)
|
-
|
Other
|
|
|
|
|
Nexium
|
461
|
10
|
-
|
1
|
Synagis
|
230
|
5
|
(6)
|
(6)
|
Losec/Prilosec
|
68
|
1
|
(9)
|
(7)
|
Seroquel XR
|
67
|
1
|
(67)
|
(66)
|
Movantik/Moventig
|
30
|
1
|
76
|
76
|
FluMist/Fluenz
|
0
|
0
|
(100)
|
(100)
|
Others
|
142
|
3
|
(56)
|
(56)
|
Total Other
|
998
|
21
|
(25)
|
(24)
|
Total Product Sales
|
4,843
|
100
|
(13)
|
(12)
|
|
$m
|
% of Total
|
% change
|
|||
Actual
|
CER
|
|||||
|
|
|
|
|
||
Emerging
Markets1
|
1,562
|
32
|
7
|
9
|
||
|
China
|
782
|
16
|
1
|
7
|
|
|
Ex. China
|
780
|
16
|
13
|
12
|
|
|
|
|
|
|
||
US
|
1,485
|
31
|
(34)
|
(34)
|
||
|
|
|
|
|
||
Europe
|
1,129
|
23
|
(7)
|
(3)
|
||
|
|
|
|
|
||
Established
ROW2
|
667
|
14
|
5
|
2
|
||
|
Japan
|
450
|
9
|
5
|
3
|
|
|
Canada
|
125
|
3
|
8
|
3
|
|
|
Other Established ROW
|
92
|
2
|
1
|
(3)
|
|
|
|
|
|
|
||
|
|
|
|
|
||
Total
|
4,843
|
100
|
(13)
|
(12)
|
|
Reported
|
% change
|
|
Core1
|
% change
|
||||
Q1 2017 ($m)
|
Q12016 ($m)
|
Actual
|
CER
|
|
Q12017 ($m)
|
Q1 2016 ($m)
|
Actual
|
CER
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit
|
4,511
|
5,111
|
(12)
|
(12)
|
|
4,578
|
5,149
|
(11)
|
(11)
|
Gross Margin2
|
82.3%
|
82.5%
|
-
|
-2
|
|
83.6%
|
83.1%
|
+1
|
-1
|
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(77)
|
(76)
|
1
|
6
|
|
(77)
|
(76)
|
1
|
6
|
% Total Revenue
|
1.4%
|
1.2%
|
-
|
-
|
|
1.4%
|
1.2%
|
-
|
-
|
R&D
Expense
|
(1,453)
|
(1,480)
|
(2)
|
2
|
|
(1,338)
|
(1,429)
|
(6)
|
(3)
|
% Total Revenue
|
26.9%
|
24.2%
|
-3
|
-3
|
|
24.8%
|
23.4%
|
-1
|
-2
|
SG&A
Expense
|
(2,300)
|
(2,572)
|
(11)
|
(8)
|
|
(1,829)
|
(2,127)
|
(14)
|
(12)
|
% Total Revenue
|
42.6%
|
42.1%
|
-
|
-1
|
|
33.8%
|
34.8%
|
+1
|
+1
|
Other
Operating Income
|
236
|
55
|
n/m
|
n/m
|
|
333
|
76
|
n/m
|
n/m
|
% Total Revenue
|
4.4%
|
0.9%
|
+3
|
+4
|
|
6.2%
|
1.2%
|
+5
|
+5
|
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
917
|
1,038
|
(12)
|
(23)
|
|
1,667
|
1,593
|
5
|
(2)
|
% Total Revenue
|
17.0%
|
17.0%
|
-
|
-3
|
|
30.8%
|
26.1%
|
+5
|
+3
|
Net
Finance Expense
|
(322)
|
(311)
|
3
|
9
|
|
(174)
|
(157)
|
11
|
15
|
Taxation
|
(70)
|
(98)
|
|
|
|
(258)
|
(249)
|
|
|
Tax
Rate
|
12%
|
14%
|
|
|
|
17%
|
17%
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
Per Share ($)
|
0.42
|
0.51
|
(17)
|
(35)
|
|
0.99
|
0.95
|
4
|
(4)
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other1
|
Core2
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Gross
Profit
|
4,511
|
38
|
29
|
-
|
-
|
4,578
|
|
|
|
|
|
|
|
R&D
Expense
|
(1,453)
|
104
|
11
|
-
|
-
|
(1,338)
|
SG&A
Expense
|
(2,300)
|
94
|
252
|
102
|
23
|
(1,829)
|
Other
Operating Income
|
236
|
76
|
21
|
-
|
-
|
333
|
|
|
|
|
|
|
|
Operating
Profit
|
917
|
312
|
313
|
102
|
23
|
1,667
|
|
|
|
|
|
|
|
Net
Finance Expense
|
(322)
|
-
|
-
|
82
|
66
|
(174)
|
|
|
|
|
|
|
|
Profit
Before Tax
|
582
|
312
|
313
|
184
|
89
|
1,480
|
|
|
|
|
|
|
|
Taxation
|
(70)
|
(66)
|
(78)
|
(37)
|
(7)
|
(258)
|
|
|
|
|
|
|
|
Earnings Per Share
($)
|
0.42
|
0.19
|
0.19
|
0.12
|
0.07
|
0.99
|
|
|
|
|
Average
Exchange Rates Versus USD
|
|
|
|
Impact
Of 5% Strengthening In Exchange Rate Versus USD ($m)1
|
||||||
Currency
|
|
Primary Relevance
|
|
FY 2016
|
|
Q1 20172
|
|
change %
|
|
Total Revenue
|
|
Core Operating Profit
|
||
EUR
|
|
Product Sales
|
|
0.90
|
|
0.94
|
|
-4%
|
|
+179
|
|
+123
|
||
JPY
|
|
Product Sales
|
|
108.84
|
|
113.74
|
|
-4%
|
|
+104
|
|
+71
|
||
CNY
|
|
Product Sales
|
|
6.65
|
|
6.87
|
|
-3%
|
|
+131
|
|
+74
|
||
SEK
|
|
Costs
|
|
8.56
|
|
8.93
|
|
-4%
|
|
+7
|
|
-98
|
||
GBP
|
|
Costs
|
|
0.74
|
|
0.81
|
|
-9%
|
|
+29
|
|
-131
|
||
Other3
|
|
|
|
|
|
|
|
|
|
+194
|
|
+124
|
||
1Based
on 2016 results at 2016 actual exchange rates.
2Based
on average daily spot rates between 1 January and 31 March
2017.
3Other
important currencies include AUD, BRL, CAD, KRW and
RUB.
|
Regulatory
Approvals
|
6
|
- Tagrisso - lung cancer (US, EU; full
approval)
- Tagrisso
- lung cancer (CN)
- Forxiga - type-2 diabetes (CN)
- Qtern - type-2 diabetes (US)
- Siliq - psoriasis (US; by partner)
|
Regulatory
Submission Acceptances
|
4
|
- Lynparza - ovarian cancer (2nd line) (US) (Priority
Review)
- Bydureon - type-2 diabetes (autoinjector)
(US)
- Symbicort - COPD exacerbations (US)
- benralizumab
- severe, uncontrolled asthma (JP)
|
Phase III or Major Data Readouts
|
2
|
- Lynparza - breast cancer
- Farxiga - type-2 diabetes (CVD-REAL
real-world study)
|
Other Key Developments
|
3
|
-
Orphan Designation: Lynparza - ovarian cancer (JP)
-
Complete
Response Letter: ZS-9 (sodium zirconium cyclosilicate) -
hyperkalaemia (US)
-
Orphan designation: inebilizumab
- neuromyelitis optica spectrum
disorder (EU)
|
New Molecular Entities(NMEs) In Phase III TrialsOr Under Regulatory
Review
|
12
|
Oncology
- durvalumab*
- multiple cancers
- durva + treme - multiple
cancers
- acalabrutinib
- blood cancers
- moxetumomab
pasudotox - leukaemia
-
selumetinib - thyroid cancer
Cardiovascular & Metabolic Diseases
- ZS-9 (sodium zirconium cyclosilicate)* -
hyperkalaemia
- roxadustat*
- anaemia
Respiratory
-
benralizumab* - severe, uncontrolled asthma, COPD
-
tralokinumab - severe, uncontrolled asthma
-
PT010 - COPD
Other
-
anifrolumab - lupus
-
lanabecestat (formerly AZD3293) - Alzheimer’s
disease
|
Projects in clinical pipeline
|
124
|
|
The following table details the ongoing Phase III trial in
metastatic urothelial cancer:
|
||||||
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
DANUBE
|
III
|
1st line
|
Cisplatin chemo-
therapy- eligible/
ineligible bladder cancer
|
durvalumab, durva + treme vs SoC chemotherapy
|
FPCD1
Q4 2015
LPCD2
Q1 20173
First data anticipated 2018
|
Recruitment completed3
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
Monotherapy
|
||||||
ADJUVANT*
|
III
|
N/A
|
Stage Ib-IIIa NSCLC
|
durvalumab vs placebo
|
FPCD Q1 2015
First data anticipated 2020
|
Recruitment ongoing
|
PACIFIC
|
III
|
N/A
|
Stage III unresectable NSCLC
|
durvalumab vs placebo
|
FPCD Q2 2014
LPCD Q2 2016
First data anticipated H2 2017
|
Recruitment completed
|
PEARL
|
III
|
1st line
|
NSCLC (Asia)
|
durvalumab vs SoC chemotherapy
|
FPCD Q1 2017
First data anticipated 2020
|
Recruitment ongoing
|
Combination therapy
|
||||||
MYSTIC
|
III
|
1st line
|
NSCLC
|
durvalumab, durva + treme vs SoC chemotherapy
|
FPCD Q3 2015
LPCD Q3 2016
First data anticipated mid-2017
|
Recruitment completed
|
NEPTUNE
|
III
|
1st line
|
NSCLC
|
durva + treme vs SoC chemotherapy
|
FPCD Q4 2015
First data anticipated 2018
|
Recruitment ongoing
|
POSEIDON
|
III
|
1st line
|
NSCLC
|
durvalumab + SoC, durva + treme + SoC vs SoC
chemotherapy
|
-
|
Recruitment initiating
|
ARCTIC
|
III
|
3rd line
|
PDL1- low/neg. NSCLC
|
durvalumab, tremelimumab, durva + treme vs SoC
chemotherapy
|
FPCD Q2 2015
LPCD Q3 2016
First data anticipated H2 2017
|
Recruitment completed
|
CASPIAN
|
III
|
1st line
|
Small-cell lung cancer (SCLC)
|
durvalumab + SoC, durva + treme + SoC vs SoC
chemotherapy
|
FPCD Q1 2017
First data anticipated 2020
|
Recruitment ongoing
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
Combination
therapy
|
||||||
KESTREL
|
III
|
1st line
|
HNSCC
|
durvalumab, durva + treme vs
SoC
|
FPCD Q4 2015
LPCD Q1 2017
First data
anticipated H2 2017
|
Recruitment completed
|
EAGLE
|
III
|
2nd line
|
HNSCC
|
durvalumab, durva + treme vs
SoC
|
First data anticipated 2018
|
Recruitment ongoing
|
Medicine
|
Trial
|
Mode of Action
|
Number of Patients
|
Primary Endpoint
|
Timeline
|
Bydureon
|
EXSCEL
|
GLP-1 agonist
|
~14,000
|
Time to first occurrence of CV death, non-fatal myocardial
infarction or non-fatal stroke
|
H2 2017
|
Farxiga
|
DECLARE
|
SGLT2 inhibitor
|
~17,000*
|
Time to first occurrence of CV death, non-fatal myocardial
infarction or non-fatal stroke
|
2019 at the latest
(final analysis)
|
Compound
|
Mechanism
|
Area
Under Investigation
|
Date
Commenced Phase
|
Estimated
Regulatory Acceptance Date / Submission Status
|
|||
US
|
EU
|
Japan
|
China
|
||||
Oncology
|
|||||||
durvalumab#
|
PD-L1
mAb
|
≥2nd-line
advanced bladder cancer
|
|
Accepted
(Breakthrough
Therapy & Priority Review)
|
|
|
|
acalabrutinib#
|
BTK
inhibitor
|
B-cell
malignancy
|
Q1
2015
|
H1
2017
(Orphan
drug)
|
|
|
|
acalabrutinib#
|
BTK
inhibitor
|
1st-line
CLL
|
Q3
2015
|
2020
(Orphan
drug)
|
2020
(Orphan
drug)
|
|
|
acalabrutinib#
|
BTK
inhibitor
|
r/r CLL, high
risk
|
Q4
2015
|
2020
(Orphan
drug)
|
2020
(Orphan
drug)
|
|
|
selumetinib
ASTRA
|
MEK
inhibitor
|
differentiated
thyroid cancer
|
Q3
2013
|
2018
(Orphan
drug)
|
2018
|
|
|
moxetumomab
pasudotox#
PLAIT
|
anti-CD22
recombinant immunotoxin
|
hairy cell
leukaemia
|
Q2
2013
|
2018
(Orphan
drug)
|
|
|
|
durvalumab#PACIFIC
|
PD-L1
mAb
|
stage III
NSCLC
|
Q2
2014
|
H2
2017
|
H2
2017
|
H2
2017
|
|
durvalumab#
PEARL
|
PD-L1
mAb
|
1st-line
NSCLC
|
Q1
2017
|
|
|
|
2019
|
durvalumab#
+
tremelimumabARCTIC
|
PD-L1 mAb + CTLA-4
mAb
|
3rd-line
NSCLC
|
Q2
2015
|
H2
2017
|
H2
2017
|
H2
2017
|
|
durvalumab#
+ tremelimumab
MYSTIC
|
PD-L1 mAb + CTLA-4
mAb
|
1st-line
NSCLC
|
Q3
2015
|
H2
2017
|
H2
2017
|
H2
2017
|
|
durvalumab#
+ tremelimumab
NEPTUNE
|
PD-L1 mAb + CTLA-4
mAb
|
1st-line
NSCLC
|
Q4
2015
|
2019
|
2019
|
2019
|
2020
|
durvalumab#
+ tremelimumab + SoC
CASPIAN
|
PD-L1 mAb + CTLA-4
mAb + SoC
|
1st-line
SCLC
|
Q1
2017
|
|
|
|
|
durvalumab#
+ tremelimumabKESTREL
|
PD-L1 mAb + CTLA-4
mAb
|
1st-line
HNSCC
|
Q4
2015
|
2018
|
2018
|
2018
|
|
durvalumab#
+ tremelimumabEAGLE
|
PD-L1 mAb + CTLA-4
mAb
|
2nd-line
HNSCC
|
Q4
2015
|
2018
|
2018
|
2018
|
|
durvalumab#
+ tremelimumab
DANUBE
|
PD-L1 mAb + CTLA-4
mAb
|
1st-line bladder
cancer
|
Q4
2015
|
2018
|
2018
|
2018
|
|
Lynparza¶ + cediranib CONCERTO
|
PARP inhibitor +
VEGF inhibitor
|
recurrent
platinum-resistant ovarian cancer
|
Q1
2017
|
2020
|
|
|
|
Cardiovascular
& Metabolic Diseases
|
|||||||
|
|
|
|
|
|
|
|
Farxiga2
|
SGLT2
inhibitor
|
type-2
diabetes
|
|
Launched
|
Launched
|
Launched
|
Approved
|
Epanova
|
omega-3
carboxylic acids
|
severe
hypertriglyceridemia
|
|
Approved
|
|
2018
|
|
ZS-9
(sodium zirconium cyclosilicate)
|
potassium
binder
|
hyperkalaemia
|
|
-
|
Accepted
|
2019
|
|
roxadustat#
OLYMPUS (US) ROCKIES
(US)
|
hypoxia-inducible
factor prolyl hydroxylase inhibitor
|
anaemia
in CKD/ESRD
|
Q3
2014
|
2018
|
|
|
Initiated3
|
Respiratory
|
|||||||
Bevespi Aerosphere (PT003)
|
LABA/LAMA
|
COPD
|
|
Launched
|
H1
2017
|
2018
|
2018
|
benralizumab#
CALIMA
SIROCCO ZONDA BISE
BORA
GREGALE
|
IL-5R
mAb
|
severe
asthma
|
|
Accepted
|
Accepted
|
Accepted
|
2020
|
benralizumab#
TERRANOVA
GALATHEA
|
IL-5R
mAb
|
COPD
|
Q3
2014
|
2018
|
2018
|
2019
|
|
PT010
|
LABA/LAMA/
ICS
|
COPD
|
Q3
2015
|
2019
|
2019
|
2018
|
2019
|
tralokinumab
STRATOS
1,2 TROPOS
MESOS
|
IL-13
mAb
|
severe
asthma
|
Q3
2014
|
2018
|
2018
|
2018
|
|
Other
|
|||||||
anifrolumab#
TULIP
|
IFN-alphaR
mAb
|
systemic
lupus erythematosus
|
Q3
2015
|
2019
(Fast
Track)
|
2019
|
2019
|
|
lanabecestat#
(AZD3293)
AMARANTH
+ extension, DAYBREAK-ALZ
|
beta-secretase
inhibitor
|
Alzheimer’s
disease
|
Q2
2016
|
2020
(Fast
Track)
|
2020
|
2020
|
|
Compound
|
Mechanism
|
Area
Under Investigation
|
Phase
|
Date
Commenced Phase
|
Oncology
|
||||
durvalumab#
|
PD-L1
mAb
|
solid
tumours
|
II
|
Q3
2014
|
durvalumab#
+ tremelimumab
|
PD-L1 mAb + CTLA-4
mAb
|
hepatocellular
carcinoma (liver cancer)
|
II
|
Q4
2016
|
durvalumab#
+ tremelimumab
|
PD-L1 mAb + CTLA-4
mAb
|
gastric
cancer
|
II
|
Q2
2015
|
durvalumab#
+ AZD5069
|
PD-L1
mAb + CXCR2
|
HNSCC
|
II
|
Q3
2015
|
durvalumab#
+ AZD9150#
|
PD-L1
mAb + STAT3 inhibitor
|
|||
durvalumab#
+ dabrafenib +
trametinib
|
PD-L1
mAb+ BRAF inhibitor + MEK inhibitor
|
melanoma
|
I
|
Q1
2014
|
durvalumab#
+ AZD1775#
|
PD-L1
mAb + Wee1 inhibitor
|
solid
tumours
|
I
|
Q4
2015
|
durvalumab#
+ MEDI0680
|
PD-L1
mAb + PD-1 mAb
|
solid
tumours
|
II
|
Q3
2016
|
durvalumab#
or durvalumab# + (tremelimumab or AZD9150#)
|
PD-L1
mAb or PD-L1 mAb + (CTLA-4 mAb or STAT3 inhibitor)
|
diffuse
large B-cell lymphoma
|
I
|
Q3
2016
|
durvalumab#
+
Iressa
|
PD-L1
mAb+ EGFR inhibitor
|
NSCLC
|
I
|
Q2
2014
|
durvalumab#
+ MEDI0562#
|
PD-L1
mAb + humanised OX40 agonist
|
solid
tumours
|
I
|
Q2
2016
|
durvalumab#
+ MEDI9447
|
PD-L1
mAb + CD73 mAb
|
solid
tumours
|
I
|
Q1
2016
|
durvalumab#
+ monalizumab
|
PD-L1
mAb + NKG2a mAb
|
solid
tumours
|
I
|
Q1
2016
|
durvalumab#
+ selumetinib
|
PD-L1
mAb + MEK inhibitor
|
solid
tumours
|
I
|
Q4
2015
|
durvalumab#
+ tremelimumab
|
PD-L1
mAb + CTLA-4 mAb
|
solid
tumours
|
I
|
Q4
2013
|
tremelimumab + MEDI0562#
|
CTLA-4
mAb + humanised OX40 agonist
|
solid
tumours
|
I
|
Q2
2016
|
Lynparza + AZD6738
|
PARP
inhibitor + ATR inhibitor
|
gastric
cancer
|
II
|
Q3
2016
|
Lynparza + AZD1775#
|
PARP
inhibitor + Wee1 inhibitor
|
solid
tumours
|
I
|
Q3
2015
|
savolitinib#
|
MET
inhibitor
|
papillary
renal cell carcinoma
|
II
|
Q2
2014
|
Tagrisso + (selumetinib#
or savolitinib#)TATTON
|
EGFR
inhibitor + (MEK inhibitor or MET inhibitor)
|
advanced
EGFRm NSCLC
|
II
|
Q2
2016
|
Tagrisso BLOOM
|
EGFR
inhibitor
|
CNS
metastases in advanced EGFRm NSCLC
|
II
|
Q4
2015
|
AZD1775#
+ chemotherapy
|
Wee1
inhibitor + chemotherapy
|
ovarian
cancer
|
II
|
Q4
2012
|
AZD1775#
|
Wee1
inhibitor
|
solid
tumours
|
II
|
Q1
2016
|
vistusertib
(AZD2014)
|
mTOR
inhibitor
|
solid
tumours
|
II
|
Q1
2013
|
AZD5363#
|
AKT
inhibitor
|
breast
cancer
|
II
|
Q1
2014
|
AZD4547
|
FGFR
inhibitor
|
solid
tumours
|
II
|
Q4
2011
|
MEDI-573#
|
IGF
mAb
|
metastatic
breast cancer
|
II
|
Q2
2012
|
AZD0156
|
ATM
inhibitor
|
solid
tumours
|
I
|
Q4
2015
|
AZD2811#
|
Aurora
B inhibitor
|
solid
tumours
|
I
|
Q4
2015
|
AZD4635
|
A2aR
inhibitor
|
solid
tumours
|
I
|
Q2
2016
|
AZD6738
|
ATR
inhibitor
|
solid
tumours
|
I
|
Q4
2013
|
AZD8186
|
PI3k
inhibitor
|
solid
tumours
|
I
|
Q2
2013
|
AZD9150#
|
STAT3
inhibitor
|
haematological
malignancies
|
I
|
Q1
2012
|
AZD9496
|
selective
oestrogen receptor downregulator (SERD)
|
ER+
breast cancer
|
I
|
Q4
2014
|
MEDI-565#
|
CEA
BiTE mAb
|
solid
tumours
|
I
|
Q1
2011
|
MEDI0562#
|
humanised
OX40 agonist
|
solid
tumours
|
I
|
Q1
2015
|
MEDI0680
|
PD-1
mAb
|
solid
tumours
|
I
|
Q4
2013
|
MEDI1873
|
GITR
agonist fusion protein
|
solid
tumours
|
I
|
Q4
2015
|
MEDI3726#
|
PSMA
antibody drug conjugate
|
prostate
cancer
|
I
|
Q1
2017
|
MEDI4276
|
HER2
bi-specific antibody drug conjugate
|
solid
tumours
|
I
|
Q4
2015
|
MEDI5083
|
immune
activator
|
solid
tumours
|
I
|
Q1
2017
|
MEDI9197#
|
TLR
7/8 agonist
|
solid
tumours
|
I
|
Q4
2015
|
MEDI9447
|
CD73
mAb
|
solid
tumours
|
I
|
Q3
2015
|
Cardiovascular & Metabolic Diseases
|
||||
MEDI0382
|
GLP-1/
glucagon
dual agonist
|
diabetes
/ obesity
|
II
|
Q3
2016
|
MEDI4166
|
PCSK9/GLP-1
mAb + peptide fusion
|
diabetes
/ cardiovascular
|
II
|
Q1
2016
|
MEDI6012
|
LCAT
|
ACS
|
II
|
Q4
2015
|
AZD4076
|
anti-miR103/107
oligonucleotide
|
non-alcoholic
fatty liver disease/non-alcoholic steatohepatitis
(NASH)
|
II
|
Q4
2016
|
AZD4831
|
myeloperoxidase
|
HF
with a preserved ejection fraction
|
I
|
Q3
2016
|
MEDI5884#
|
cholesterol
modulation
|
cardiovascular
|
I
|
Q1
2017
|
AZD5718
|
FLAP
|
CAD
|
I
|
Q1
2016
|
AZD8601#
|
VEGF-A
|
cardiovascular
|
I
|
Q1
2017
|
MEDI8111
|
Rh-factor
II
|
trauma
/ bleeding
|
I
|
Q1
2014
|
Respiratory
|
||||
tezepelumab#
|
TSLP
mAb
|
asthma
/ atopic dermatitis
|
II
|
Q2
2014
|
abediterol#
|
LABA
|
asthma/COPD
|
II
|
Q4
2007
|
AZD7594
|
inhaled
SGRM
|
asthma/COPD
|
II
|
Q3
2015
|
PT010
|
LABA/LAMA/ICS
|
asthma
|
II
|
Q2
2014
|
AZD1419#
|
inhaled
TLR9 agonist
|
asthma
|
II
|
Q4
2016
|
AZD8871#
|
MABA
|
COPD
|
II
|
Q1
2017
|
AZD0284
|
RORg
|
psoriasis/respiratory
|
I
|
Q4
2016
|
AZD5634
|
inhaled
ENaC
|
cystic
fibrosis
|
I
|
Q1
2016
|
AZD7594+abediterol#
|
inhaled
SGRM+LABA
|
asthma/COPD
|
I
|
Q4
2016
|
AZD7986#
|
DPP1
|
COPD
|
I
|
Q4
2014
|
AZD9567
|
oral
SGRM
|
rheumatoid
arthritis/respiratory
|
I
|
Q4
2015
|
Other
|
||||
anifrolumab#
|
IFN-alphaR
mAb
|
lupus
nephritis
|
II
|
Q4
2015
|
anifrolumab#
|
IFN-alphaR
mAb
|
systemic
lupus erythematosus (subcutaneous)
|
II
|
Q1
2017
|
inebilizumab#
|
CD19
mAb
|
neuromyelitis
optica
|
II
(Orphan drug US,
EU)
|
Q1
2015
|
mavrilimumab#
|
GM-CSFR
mAb
|
rheumatoid
arthritis
|
II
|
Q1
2010
|
verinurad
|
selective uric acid
reabsorption inhibitor (URAT-1)
|
chronic
treatment of hyperuricemia in patients with gout
|
II
|
Q3
2013
|
MEDI5872#
|
B7RP1
mAb
|
primary
Sjögren’s
syndrome
|
II
|
Q3
2016
|
MEDI3902
|
Psl/PcrV
bispecific mAb
|
prevention of nosocomial Pseudomonas aeruginosa
pneumonia
|
II
(Fast
Track, US)
|
Q2
2016
|
MEDI4893
|
mAb binding to S. aureus toxin
|
prevention of nosocomial
Staphylococcus
aureus pneumonia
|
II
(Fast
Track, US)
|
Q4
2014
|
MEDI8852
|
influenza
A mAb
|
influenza
A treatment
|
II
(Fast Track,
US)
|
Q4
2015
|
MEDI8897#
|
RSV
mAb-YTE
|
passive
RSV prophylaxis
|
II
(Fast
Track, US)
|
Q1
2015
|
MEDI0700#
|
BAFF/B7RP1
bispecific mAb
|
systemic
lupus erythematosus
|
I
|
Q1
2016
|
MEDI1814#
|
amyloid
beta mAb
|
Alzheimer’s
disease
|
I
|
Q2
2014
|
MEDI4920
|
anti-CD40L-Tn3
fusion protein
|
primary
Sjögren’s syndrome
|
I
|
Q2
2014
|
MEDI7352
|
NGF/TNF
bispecific mAb
|
osteoarthritis
pain
|
I
|
Q1
2016
|
MEDI7734
|
ILT7
mAb
|
myositis
|
I
|
Q3
2016
|
MEDI9314
|
IL-4R
mAb
|
atopic
dermatitis
|
I
|
Q1
2016
|
Compound
|
Mechanism
|
Area
Under Investigation
|
Date
Commenced Phase
|
Estimated
Regulatory Acceptance Date / Submission Status
|
|||
US
|
EU
|
Japan
|
China
|
||||
Oncology
|
|||||||
Faslodex
FALCON
|
oestrogen
receptor antagonist
|
1st-line
hormone receptor +ve advanced breast cancer
|
|
Accepted
|
Accepted
|
Accepted
|
H2
2017
|
Lynparza OlympiAD
|
PARP
inhibitor
|
gBRCA
metastatic breast cancer
|
Q2
2014
|
H2
2017
|
2018
|
H2
2017
|
|
LynparzaSOLO-2
|
PARP
inhibitor
|
2nd-line
or greater BRCAm PSR ovarian cancer, maintenance
monotherapy
|
Q3
2013
|
Accepted
(Priority
Review)
|
H1
2017
|
H2
2017
|
|
LynparzaSOLO-1
|
PARP
inhibitor
|
1st-line
BRCAm ovarian cancer
|
Q3
2013
|
2018
|
2018
|
2018
|
|
LynparzaSOLO-3
|
PARP
inhibitor
|
gBRCA
PSR ovarian cancer
|
Q1
2015
|
2018
|
|
|
|
LynparzaPOLO
|
PARP
inhibitor
|
pancreatic
cancer
|
Q1
2015
|
2018
|
2018
|
|
|
Lynparza
PROfound
|
PARP
inhibitor
|
prostate
cancer
|
Q1
2017
|
(Breakthrough Therapy)
|
|
|
|
Lynparza
OlympiA
|
PARP
inhibitor
|
gBRCA
adjuvant breast cancer
|
Q2
2014
|
2020
|
2020
|
2020
|
|
Tagrisso
FLAURA
|
EGFR
inhibitor
|
1st-line
advanced EGFRm NSCLC
|
Q1
2015
|
H2
2017
|
H2
2017
|
H2
2017
|
H2
2017
|
Tagrisso
ADAURA
|
EGFR
inhibitor
|
adjuvant
EGFRm NSCLC
|
Q4
2015
|
2022
|
2022
|
2022
|
2022
|
Cardiovascular
& Metabolic Diseases
|
|||||||
Brilinta1
THEMIS
|
P2Y12
receptor antagonist
|
outcomes trial in patients with
type-2 diabetes and CAD, but without a previous history
of myocardial infarction or
stroke
|
Q1
2014
|
2019
|
2019
|
2019
|
2020
|
Brilinta1
HESTIA
|
P2Y12
receptor antagonist
|
prevention
of vaso-occlusive crises in paediatric patients with sickle cell
disease
|
Q1
2014
|
2020
|
2020
|
|
|
Kombiglyze XR/Komboglyze2
|
DPP-4
inhibitor/ metformin FDC
|
type-2
diabetes
|
|
Launched
|
Launched
|
|
Accepted
|
Farxiga3DECLARE-TIMI
58
|
SGLT2
inhibitor
|
type-2
diabetes outcomes trial
|
Q2
2013
|
2020
|
2020
|
|
|
Farxiga3
|
SGLT2
inhibitor
|
type-1
diabetes
|
Q4
2014
|
2018
|
2018
|
2018
|
|
Farxiga3
|
SGLT2
inhibitor
|
effect
of dapagliflozin on the incidence of worsening HF or cardiovascular
death in patients with chronic HF
|
Q1
2017
|
2020
|
2020
|
2020
|
2020
|
Farxiga3
|
SGLT2
inhibitor
|
renal outcomes and
cardiovascular mortality in patients with
CKD
|
Q1
2017
|
2021
|
2021
|
N/A
|
2021
|
Xigduo XR/
Xigduo4
|
SGLT2
inhibitor/ metformin FDC
|
type-2
diabetes
|
|
Launched
|
Launched
|
|
|
Qtern (saxagliptin/
dapagliflozin
FDC)
|
DPP-4
inhibitor/ SGLT2 inhibitor FDC
|
type-2
diabetes
|
|
Approved
|
Launched
|
|
|
Bydureon weekly autoinjector
|
GLP-1
receptor agonist
|
type-2
diabetes
|
Q1
2013
|
Accepted
|
H2
2017
|
|
|
Bydureon EXSCEL
|
GLP-1
receptor agonist
|
type-2
diabetes outcomes trial
|
Q2
2010
|
H2
2017
|
H2
2017
|
|
2018
|
Epanova
STRENGTH
|
omega-3
carboxylic acids
|
outcomes
trial in statin-treated patients at high CV risk, with persistent
hypertriglyceridemia plus low HDL-cholesterol
|
Q4
2014
|
2020
|
2020
|
2020
|
2020
|
Respiratory
|
|||||||
Symbicort
SYGMA
|
ICS/LABA
|
as-needed
use in mild asthma
|
Q4
2014
|
|
2018
|
|
2019
|
Duaklir Genuair#
|
LAMA/LABA
|
COPD
|
|
2018
|
Launched
|
|
2019
|
Other
|
|||||||
Nexium
|
proton
pump inhibitor
|
stress
ulcer prophylaxis
|
|
|
|
|
Submitted
|
Nexium
|
proton
pump inhibitor
|
paediatrics
|
|
Launched
|
Launched
|
Accepted
|
|
linaclotide#
|
GC-C
receptor peptide agonist
|
irritable
bowel syndrome with constipation (IBS-C)
|
|
|
|
|
Accepted
|
NME / Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
Symbicort - breath actuated
inhaler
|
ICS/LABA
|
Strategic
|
asthma/COPD
|
AZD3241
|
myeloperoxidase
inhibitor
|
Safety/Efficacy
|
multiple system atrophy
|
AZD9412#
|
inhaled
interferon beta
|
Strategic
|
asthma/COPD
|
Compound
|
Mechanism
|
Area
Under Investigation
|
Completed/
Divested
|
Estimated
Regulatory Submission Acceptance†
|
|||
US
|
EU
|
Japan
|
China
|
||||
Tagrisso
AURA, AURA2,
(AURA17 Asia regional)
|
EGFR
inhibitor
|
≥2nd-line
advanced EGFRm T790M NSCLC
|
Completed
|
Launched
(Breakthrough
Therapy, Priority Review, Orphan drug)
|
Launched
(Accelerated
assessment)
|
Launched
|
Launched
|
Tagrisso
AURA3
|
EGFR
inhibitor
|
≥2nd-line
advanced EGFRm T790M NSCLC
|
Completed
|
Launched
|
Launched
|
|
|
Brilinta1
|
P2Y12
receptor antagonist
|
arterial
thrombosis
|
Completed
|
Launched
|
Launched
|
Launched
|
Launched
|
Onglyza
SAVOR-TIMI
53
|
DPP-4
inhibitor
|
type-2
diabetes outcomes trial
|
Completed
|
Launched
|
Launched
|
|
Launched
|
For the
quarter ended 31
March
|
|
2017
$m
|
|
2016
$m
|
Product
sales
|
|
4,843
|
|
5,565
|
Externalisation
revenue
|
|
562
|
|
550
|
Total revenue
|
|
5,405
|
|
6,115
|
Cost of
sales
|
|
(894)
|
|
(1,004)
|
Gross profit
|
|
4,511
|
|
5,111
|
Distribution
costs
|
|
(77)
|
|
(76)
|
Research
and development expense
|
|
(1,453)
|
|
(1,480)
|
Selling,
general and administrative costs
|
|
(2,300)
|
|
(2,572)
|
Other
operating income and expense
|
|
236
|
|
55
|
Operating profit
|
|
917
|
|
1,038
|
Finance
income
|
|
18
|
|
14
|
Finance
expense
|
|
(340)
|
|
(325)
|
Share
of after tax losses in associates and joint ventures
|
|
(13)
|
|
(4)
|
Profit before tax
|
|
582
|
|
723
|
Taxation
|
|
(70)
|
|
(98)
|
Profit for the period
|
|
512
|
|
625
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
1
|
|
(191)
|
Tax on
items that will not be reclassified to profit or loss
|
|
(1)
|
|
41
|
|
|
-
|
|
(150)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
154
|
|
(167)
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
100
|
|
207
|
Fair
value movements on cash flow hedges
|
|
7
|
|
-
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
(39)
|
|
-
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(30)
|
|
(32)
|
Net
available for sale losses taken to equity
|
|
(150)
|
|
(29)
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
24
|
|
10
|
|
|
66
|
|
(11)
|
Other comprehensive income for the period, net of tax
|
|
66
|
|
(161)
|
Total comprehensive income for the period
|
|
578
|
|
464
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
537
|
|
646
|
Non-controlling
interests
|
|
(25)
|
|
(21)
|
|
|
512
|
|
625
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
603
|
|
485
|
Non-controlling
interests
|
|
(25)
|
|
(21)
|
|
|
578
|
|
464
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$0.42
|
|
$0.51
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$0.42
|
|
$0.51
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,265
|
|
1,264
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,266
|
|
1,265
|
|
|
At
31 Mar 2017
$m
|
|
At
31 Dec 2016
$m
|
|
Restated*
At
31 Mar 2016
$m
|
ASSETS
Non-current
assets
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
6,954
|
|
6,848
|
|
6,560
|
Goodwill
|
|
11,688
|
|
11,658
|
|
11,855
|
Intangible
assets
|
|
27,386
|
|
27,586
|
|
29,627
|
Derivative
financial instruments
|
|
310
|
|
343
|
|
419
|
Investments in
associates and joint ventures
|
|
88
|
|
99
|
|
104
|
Other
investments
|
|
739
|
|
727
|
|
500
|
Other
receivables
|
|
891
|
|
901
|
|
874
|
Deferred tax
assets
|
|
1,266
|
|
1,102
|
|
1,482
|
|
|
49,322
|
|
49,264
|
|
51,421
|
Current
assets
|
|
|
|
|
|
|
Inventories
|
|
2,652
|
|
2,334
|
|
2,344
|
Trade
and other receivables
|
|
4,686
|
|
4,573
|
|
5,881
|
Other
investments
|
|
530
|
|
884
|
|
671
|
Derivative
financial instruments
|
|
13
|
|
27
|
|
8
|
Income
tax receivable
|
|
627
|
|
426
|
|
452
|
Cash
and cash equivalents
|
|
3,129
|
|
5,018
|
|
3,428
|
|
|
11,637
|
|
13,262
|
|
12,784
|
Total
assets
|
|
60,959
|
|
62,526
|
|
64,205
|
LIABILITIES
Current
liabilities
|
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(2,839)
|
|
(2,307)
|
|
(2,168)
|
Trade
and other payables
|
|
(9,899)
|
|
(10,486)
|
|
(11,174)
|
Derivative
financial instruments
|
|
(1)
|
|
(18)
|
|
(4)
|
Provisions
|
|
(1,044)
|
|
(1,065)
|
|
(790)
|
Income
tax payable
|
|
(1,646)
|
|
(1,380)
|
|
(1,796)
|
|
|
(15,429)
|
|
(15,256)
|
|
(15,932)
|
Non-current
liabilities
|
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(14,563)
|
|
(14,501)
|
|
(14,144)
|
Derivative
financial instruments
|
|
(107)
|
|
(117)
|
|
-
|
Deferred tax
liabilities
|
|
(4,036)
|
|
(3,956)
|
|
(4,302)
|
Retirement benefit
obligations
|
|
(2,171)
|
|
(2,186)
|
|
(2,099)
|
Provisions
|
|
(378)
|
|
(353)
|
|
(461)
|
Other
payables
|
|
(9,496)
|
|
(9,488)
|
|
(10,625)
|
|
|
(30,751)
|
|
(30,601)
|
|
(31,631)
|
Total
liabilities
|
|
(46,180)
|
|
(45,857)
|
|
(47,563)
|
Net
assets
|
|
14,779
|
|
16,669
|
|
16,642
|
EQUITY
|
|
|
|
|
|
|
Capital
and reserves attributable to equity holders of the
Company
|
|
|
|
|
|
|
Share
capital
|
|
316
|
|
316
|
|
316
|
Share
premium account
|
|
4,368
|
|
4,351
|
|
4,322
|
Other
reserves
|
|
2,042
|
|
2,047
|
|
2,028
|
Retained
earnings
|
|
6,263
|
|
8,140
|
|
8,075
|
|
|
12,989
|
|
14,854
|
|
14,741
|
Non-controlling
interests
|
|
1,790
|
|
1,815
|
|
1,901
|
Total
equity
|
|
14,779
|
|
16,669
|
|
16,642
|
*31
March comparatives have been restated to reflect an adjustment to
the acquisition-accounting for ZS Pharma (as detailed in Note 25 of
the AstraZeneca Annual Report and Form 20-F Information 2016, page
174) and an adjustment to the acquisition-accounting for Acerta
Pharma (as detailed in Note 4 of the Full Year and Fourth Quarter
2016 Results Announcement).
|
For the
quarter ended 31 March
|
|
2017
$m
|
|
2016
$m
|
Cash
flows from operating activities
|
|
|
|
|
Profit
before tax
|
|
582
|
|
723
|
Finance
income and expense
|
|
322
|
|
311
|
Share
of after tax losses in associates and joint ventures
|
|
13
|
|
4
|
Depreciation,
amortisation and impairment
|
|
658
|
|
569
|
(Increase)/decrease
in working capital and short-term provisions
|
|
(887)
|
|
64
|
Non-cash and other
movements
|
|
(349)
|
|
(88)
|
Cash
generated from operations
|
|
339
|
|
1,583
|
Interest
paid
|
|
(189)
|
|
(185)
|
Tax
paid
|
|
(62)
|
|
(205)
|
Net
cash inflow from operating activities
|
|
88
|
|
1,193
|
Cash
flows from investing activities
|
|
|
|
|
Movement in
short-term investments and fixed deposits
|
|
357
|
|
33
|
Purchase of
property, plant and equipment
|
|
(286)
|
|
(267)
|
Disposal of
property, plant and equipment
|
|
9
|
|
2
|
Purchase of
intangible assets
|
|
(99)
|
|
(39)
|
Disposal of
intangible assets
|
|
51
|
|
-
|
Purchase of
non-current asset investments
|
|
(18)
|
|
(68)
|
Disposal of
non-current asset investments
|
|
8
|
|
-
|
Upfront
payments on business combinations
|
|
-
|
|
(2,564)
|
Payment
of contingent consideration on business combinations
|
|
(213)
|
|
(26)
|
Interest
received
|
|
45
|
|
42
|
Net
cash outflow from investing activities
|
|
(146)
|
|
(2,887)
|
Net
cash outflow before financing activities
|
|
(58)
|
|
(1,694)
|
Cash
flows from financing activities
|
|
|
|
|
Proceeds from issue
of share capital
|
|
17
|
|
18
|
New
long term loans
|
|
3
|
|
-
|
Dividends
paid
|
|
(2,368)
|
|
(2,409)
|
Hedge
contracts relating to dividend payments
|
|
(32)
|
|
5
|
Repayment of
obligations under finance leases
|
|
(14)
|
|
(3)
|
Movement in
short-term borrowings
|
|
352
|
|
1,028
|
Net
cash outflow from financing activities
|
|
(2,042)
|
|
(1,361)
|
Net
decrease in cash and cash equivalents in the period
|
|
(2,100)
|
|
(3,055)
|
Cash
and cash equivalents at the beginning of the period
|
|
4,924
|
|
6,051
|
Exchange rate
effects
|
|
14
|
|
43
|
Cash
and cash equivalents at the end of the period
|
|
2,838
|
|
3,039
|
Cash
and cash equivalents consists of:
|
|
|
|
|
Cash
and cash equivalents
|
|
3,129
|
|
3,428
|
Overdrafts
|
|
(291)
|
|
(389)
|
|
|
2,838
|
|
3,039
|
|
|
|
|
|
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
At
1 Jan 2016
|
|
316
|
|
4,304
|
|
2,036
|
|
11,834
|
|
18,490
|
|
19
|
|
18,509
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
646
|
|
646
|
|
(21)
|
|
625
|
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
(161)
|
|
(161)
|
|
-
|
|
(161)
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
(8)
|
|
8
|
|
-
|
|
-
|
|
-
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(2,402)
|
|
(2,402)
|
|
-
|
|
(2,402)
|
Acerta
put option
|
|
-
|
|
-
|
|
-
|
|
(1,825)
|
|
(1,825)
|
|
-
|
|
(1,825)
|
Changes
in non-controlling interest
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1,903
|
|
1,903
|
Issue
of Ordinary Shares
|
|
-
|
|
18
|
|
-
|
|
-
|
|
18
|
|
-
|
|
18
|
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(25)
|
|
(25)
|
|
-
|
|
(25)
|
Net
movement
|
|
-
|
|
18
|
|
(8)
|
|
(3,759)
|
|
(3,749)
|
|
1,882
|
|
(1,867)
|
At
31 Mar 2016
|
|
316
|
|
4,322
|
|
2,028
|
|
8,075
|
|
14,741
|
|
1,901
|
|
16,642
|
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
At
1 Jan 2017
|
|
316
|
|
4,351
|
|
2,047
|
|
8,140
|
|
14,854
|
|
1,815
|
|
16,669
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
537
|
|
537
|
|
(25)
|
|
512
|
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
66
|
|
66
|
|
-
|
|
66
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
(5)
|
|
5
|
|
-
|
|
-
|
|
-
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(2,404)
|
|
(2,404)
|
|
-
|
|
(2,404)
|
Issue
of Ordinary Shares
|
|
-
|
|
17
|
|
-
|
|
-
|
|
17
|
|
-
|
|
17
|
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(81)
|
|
(81)
|
|
-
|
|
(81)
|
Net
movement
|
|
-
|
|
17
|
|
(5)
|
|
(1,877)
|
|
(1,865)
|
|
(25)
|
|
(1,890)
|
At
31 Mar 2017
|
|
316
|
|
4,368
|
|
2,042
|
|
6,263
|
|
12,989
|
|
1,790
|
|
14,779
|
|
|
|
|
|
|
Q1
2017$m
|
|
Q1
2016$m
|
Cost of
sales
|
|
|
|
|
|
38
|
|
9
|
Research and
development expense
|
|
|
|
|
|
104
|
|
38
|
Selling, general
and administrative costs
|
|
|
|
|
|
94
|
|
108
|
Other
operating income and expense
|
|
|
|
|
|
76
|
|
-
|
Total
|
|
|
|
|
|
312
|
|
155
|
|
|
At 1 Jan
2017
$m
|
|
Cash
Flow
$m
|
|
Non-cash
&
Other
$m
|
|
Exchange
Movements
$m
|
|
At
31 Mar
2017
$m
|
Loans
due after one year
|
|
(14,495)
|
|
(3)
|
|
(2)
|
|
(60)
|
|
(14,560)
|
Finance
leases due after one year
|
|
(6)
|
|
-
|
|
3
|
|
-
|
|
(3)
|
Total
long-term debt
|
|
(14,501)
|
|
(3)
|
|
1
|
|
(60)
|
|
(14,563)
|
|
|
|
|
|
|
|
|
|
|
|
Current
instalments of loans
|
|
(1,769)
|
|
-
|
|
7
|
|
-
|
|
(1,762)
|
Current
instalments of finance leases
|
|
(87)
|
|
14
|
|
(4)
|
|
-
|
|
(77)
|
Total
current debt
|
|
(1,856)
|
|
14
|
|
3
|
|
-
|
|
(1,839)
|
|
|
|
|
|
|
|
|
|
|
|
Other
investments
|
|
898
|
|
(353)
|
|
-
|
|
3
|
|
548
|
Net
derivative financial instruments
|
|
235
|
|
32
|
|
(52)
|
|
-
|
|
215
|
Cash
and cash equivalents
|
|
5,018
|
|
(1,903)
|
|
-
|
|
14
|
|
3,129
|
Overdrafts
|
|
(94)
|
|
(197)
|
|
-
|
|
-
|
|
(291)
|
Short-term
borrowings
|
|
(357)
|
|
(352)
|
|
-
|
|
-
|
|
(709)
|
|
|
5,700
|
|
(2,773)
|
|
(52)
|
|
17
|
|
2,892
|
Net
debt
|
|
(10,657)
|
|
(2,762)
|
|
(48)
|
|
(43)
|
|
(13,510)
|
|
|
Diabetes
Alliance
2017
|
|
Other
2017
|
|
Total
2017
|
|
Total
2016
|
|
|
$m
|
|
$m
|
|
$m
|
|
$m
|
At
1 January
|
|
4,240
|
|
1,217
|
|
5,457
|
|
6,411
|
Settlements
|
|
(138)
|
|
(75)
|
|
(213)
|
|
(26)
|
Discount
unwind
|
|
82
|
|
22
|
|
104
|
|
124
|
At
31 March
|
|
4,184
|
|
1,164
|
|
5,348
|
|
6,509
|
|
World
|
|
Emerging Markets
|
|
US
|
|
Europe
|
|
Established ROW
|
|||||||||||||||
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q1 2017
$m
|
|
Actual
%
|
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
171
|
|
n/m
|
n/m
|
|
6
|
|
n/m
|
n/m
|
|
90
|
|
100
|
|
35
|
|
n/m
|
n/m
|
|
40
|
|
n/m
|
n/m
|
|
Iressa
|
124
|
|
(8)
|
(7)
|
|
61
|
|
(9)
|
(7)
|
|
8
|
|
100
|
|
26
|
|
(24)
|
(24)
|
|
29
|
|
(3)
|
(3)
|
|
Lynparza
|
57
|
|
30
|
32
|
|
4
|
|
100
|
150
|
|
27
|
|
(4)
|
|
25
|
|
79
|
79
|
|
1
|
|
n/m
|
n/m
|
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
214
|
|
13
|
13
|
|
27
|
|
29
|
24
|
|
118
|
|
19
|
|
54
|
|
(4)
|
(2)
|
|
15
|
|
7
|
7
|
|
Zoladex
|
185
|
|
4
|
5
|
|
87
|
|
30
|
31
|
|
8
|
|
(20)
|
|
32
|
|
(18)
|
(13)
|
|
58
|
|
(6)
|
(8)
|
|
Casodex
|
56
|
|
(10)
|
(8)
|
|
30
|
|
3
|
7
|
|
-
|
|
-
|
|
6
|
|
(14)
|
(14)
|
|
20
|
|
(23)
|
(23)
|
|
Arimidex
|
52
|
|
(9)
|
(7)
|
|
29
|
|
-
|
3
|
|
1
|
|
(75)
|
|
8
|
|
-
|
-
|
|
14
|
|
(13)
|
(13)
|
|
Others
|
26
|
|
24
|
24
|
|
7
|
|
-
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
-
|
|
18
|
|
38
|
38
|
|
Total Oncology
|
885
|
|
20
|
21
|
|
251
|
|
14
|
16
|
|
252
|
|
33
|
|
187
|
|
13
|
14
|
|
195
|
|
21
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta/Brilique
|
224
|
|
24
|
27
|
|
60
|
|
46
|
54
|
|
87
|
|
24
|
|
65
|
|
8
|
12
|
|
12
|
|
20
|
20
|
|
Farxiga/Forxiga
|
207
|
|
25
|
25
|
|
42
|
|
100
|
90
|
|
96
|
|
2
|
|
50
|
|
22
|
24
|
|
19
|
|
111
|
111
|
|
Onglyza
|
154
|
|
(27)
|
(27)
|
|
30
|
|
(17)
|
(17)
|
|
81
|
|
(35)
|
|
27
|
|
(18)
|
(18)
|
|
16
|
|
(11)
|
(11)
|
|
Bydureon
|
153
|
|
13
|
14
|
|
1
|
|
(50)
|
-
|
|
127
|
|
18
|
|
22
|
|
(4)
|
(4)
|
|
3
|
|
50
|
50
|
|
Byetta
|
46
|
|
(26)
|
(24)
|
|
5
|
|
-
|
20
|
|
30
|
|
(29)
|
|
8
|
|
(20)
|
(20)
|
|
3
|
|
(40)
|
(40)
|
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
631
|
|
(45)
|
(44)
|
|
202
|
|
10
|
14
|
|
112
|
|
(82)
|
|
195
|
|
(8)
|
(4)
|
|
122
|
|
(2)
|
(4)
|
|
Seloken/Toprol-XL
|
186
|
|
1
|
3
|
|
152
|
|
9
|
11
|
|
11
|
|
(48)
|
|
21
|
|
(5)
|
(5)
|
|
2
|
|
-
|
-
|
|
Atacand
|
75
|
|
4
|
7
|
|
44
|
|
26
|
31
|
|
6
|
|
(33)
|
|
21
|
|
(13)
|
(13)
|
|
4
|
|
-
|
-
|
|
Others
|
103
|
|
(18)
|
(16)
|
|
58
|
|
(29)
|
(26)
|
|
14
|
|
180
|
|
23
|
|
(23)
|
(23)
|
|
8
|
|
(11)
|
(11)
|
|
Total CVMD
|
1,779
|
|
(22)
|
(21)
|
|
594
|
|
9
|
12
|
|
564
|
|
(49)
|
|
432
|
|
(5)
|
(3)
|
|
189
|
|
3
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
677
|
|
(10)
|
(8)
|
|
112
|
|
7
|
10
|
|
255
|
|
(21)
|
|
200
|
|
(13)
|
(9)
|
|
110
|
|
21
|
16
|
|
Pulmicort
|
337
|
|
9
|
14
|
|
250
|
|
21
|
28
|
|
41
|
|
(27)
|
|
26
|
|
(10)
|
(7)
|
|
20
|
|
11
|
11
|
|
Daliresp/Daxas
|
44
|
|
42
|
42
|
|
1
|
|
n/m
|
n/m
|
|
38
|
|
23
|
|
5
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
Tudorza/Eklira
|
37
|
|
(5)
|
(3)
|
|
-
|
|
-
|
-
|
|
15
|
|
(12)
|
|
20
|
|
(5)
|
-
|
|
2
|
|
100
|
100
|
|
Duaklir
|
19
|
|
46
|
54
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
|
19
|
|
58
|
58
|
|
-
|
|
-
|
-
|
|
Others
|
67
|
|
3
|
6
|
|
27
|
|
(29)
|
(24)
|
|
3
|
|
(25)
|
|
28
|
|
40
|
40
|
|
9
|
|
200
|
200
|
|
Total Respiratory
|
1,181
|
|
(2)
|
-
|
|
390
|
|
11
|
17
|
|
352
|
|
(18)
|
|
298
|
|
(5)
|
(1)
|
|
141
|
|
25
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
461
|
|
-
|
1
|
|
175
|
|
(1)
|
3
|
|
136
|
|
4
|
|
61
|
|
2
|
3
|
|
89
|
|
(6)
|
(9)
|
|
Synagis
|
230
|
|
(6)
|
(6)
|
|
-
|
|
-
|
-
|
|
157
|
|
(2)
|
|
73
|
|
(13)
|
(13)
|
|
-
|
|
-
|
-
|
|
Losec/Prilosec
|
68
|
|
(9)
|
(7)
|
|
35
|
|
(10)
|
(5)
|
|
5
|
|
150
|
|
18
|
|
(14)
|
(14)
|
|
10
|
|
(23)
|
(23)
|
|
Seroquel XR
|
67
|
|
(67)
|
(66)
|
|
15
|
|
(17)
|
(11)
|
|
24
|
|
(83)
|
|
22
|
|
(37)
|
(37)
|
|
6
|
|
20
|
20
|
|
Movantik/Moventig
|
30
|
|
76
|
76
|
|
-
|
|
-
|
-
|
|
30
|
|
76
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
FluMist/Fluenz
|
-
|
|
(100)
|
(100)
|
|
-
|
|
-
|
-
|
|
-
|
|
(100)
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
Others
|
142
|
|
(56)
|
(56)
|
|
102
|
|
(10)
|
(23)
|
|
(35)
|
|
n/m
|
|
38
|
|
(57)
|
(30)
|
|
37
|
|
(43)
|
(55)
|
|
Total Other
|
998
|
|
(25)
|
(24)
|
|
327
|
|
(2)
|
(3)
|
|
317
|
|
(39)
|
|
212
|
|
(5)
|
(1)
|
|
142
|
|
(2)
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL PRODUCT SALES
|
4,843
|
|
(13)
|
(12)
|
|
1,562
|
|
7
|
9
|
|
1,485
|
|
(34)
|
|
1,129
|
|
(7)
|
(3)
|
|
667
|
|
5
|
2
|
Annual
General Meeting
|
|
27
April 2017
|
Announcement
of half year and second quarter 2017 results
|
|
27 July
2017
|
Announcement
of nine months and third quarter 2017 results
|
|
9
November 2017
|
|
Addresses
for Correspondence
|
||||
Registered Office
1
Francis Crick Avenue
Cambridge
Biomedical Campus, Cambridge
CB2
0AA
UK
|
Registrar and
Transfer Office
Equiniti
Limited
Aspect
House
Spencer
Road
Lancing
West
Sussex
BN99
6DA
UK
|
Swedish Central Securities Depository
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
Sweden
|
US Depositary
Citibank Shareholder Services
PO Box
43077
Providence
RI
02940-3077
USA
|
|
Tel:
+44 (0)20 3749 5000
|
Tel
(freephone in UK):
0800
389 1580
Tel
(outside UK): +44 (0)121 415 7033
|
Tel:
+46 (0)8 402 9000
|
Tel:
(toll free in the US)
+1
(888) 697 8018
Tel:
(outside the US)
+1
(781) 575 4555
citibank@shareholders-online.com
|
|
Cautionary
Statements Regarding Forward-Looking Statements
|
Date:
27 April 2017
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|